Peregrine Pharmaceuticals, Inc. (PPHM)
-NasdaqCM 1.62 
0.04(2.53%) 4:00PM EDT|After Hours
:
1.65 0.03 (1.85%) 7:55PM EDT
| Prev Close: | 1.58 |
|---|
| Open: | 1.51 |
|---|
| Bid: | 1.61 x 400 |
|---|
| Ask: | 1.70 x 500 |
|---|
| 1y Target Est: | 4.00 |
|---|
| Beta: | 1.56 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 1.50 - 1.63 |
|---|
| 52wk Range: | 0.42 - 5.50 |
|---|
| Volume: | 2,573,089 |
|---|
| Avg Vol (3m): | 2,595,160 |
|---|
| Market Cap: | 222.12M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapyat Seeking Alpha(Thu 5:49PM EDT)
- FDA Green Light = Surprise Share Surgeat Motley Fool(Tue, May 21)
- These Winners Couldn't Send the Dow to Another Recordat Motley Fool(Mon, May 20)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Small-cap makes a splash with FDA nod for cancer drugat MarketWatch(Mon, May 20)
- Movers roundup: WPX Energy, PeregrineAP(Mon, May 20)
- Why Peregrine Pharmaceuticals Shares Skyrocketedat Motley Fool(Mon, May 20)
- Peregrine rises on agreement for late-stage studyAP(Mon, May 20)
- Apple Explores OLED For Its Smartwatch and 2 Other Hot Stocks to Watchat Wall St. Cheat Sheet(Mon, May 20)
- Peregrine Pharma agrees with FDA on lung cancer trial designat Reuters(Mon, May 20)
- PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 20)
- Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung CancerMarketwired(Mon, May 20)
- Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual MeetingMarketwired(Thu, May 16)
- Osiris Loss In-Line with ExpectationsZacks(Wed, May 8)
- PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.11 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Apr-13)
: | -0.23 |
|---|
| Quarterly EPS Est
(Apr-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections.
View More